Share
Financial
Johnson & Johnson Reports 2016 Second-Quarter Results:
Johnson & Johnson Reports 2016 Second-Quarter Results:
Share
Sales of $18.5 Billion Increased 3.9% Versus 2015 Second Quarter

NEW BRUNSWICK, N.J., July 19, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $18.5 billion for the second quarter of 2016, an increase of 3.9% as compared to the second quarter of 2015. Operational sales results increased 5.3% and the negative impact of currency was 1.4%. Domestic sales increased 7.4%. International sales increased 0.4%, reflecting operational growth of 3.1% and a negative currency impact of 2.7%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.9%, domestic sales increased 8.8% and international sales increased 6.9%.*  Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points.  

Net earnings and diluted earnings per share for the second quarter of 2016 were $4.0 billion and $1.43, respectively.  Second quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.7 billion. Second quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.1 billion.  Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.9 billion and adjusted diluted earnings per share were $1.74, representing increases of 1.1% and 1.8%, respectively, as compared to the same period in 2015.* On an operational basis, adjusted diluted earnings per share also increased 1.8%.A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise," said Alex Gorsky, Chairman and Chief Executive Officer.  "We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline. In our Consumer business, we are executing strategic portfolio decisions to expand our market leadership in key segments, and in Medical Devices, we are continuing to accelerate our growth driven by new product launches and transforming our commercial models."

Mr. Gorsky continued, "I am proud of our dedicated and talented employees whose commitment to advancing health and well-being for patients and consumers around the world is fueling our growth."

The Company increased its sales guidance for the full-year 2016 to $71.5 billion to $72.2 billion.  Additionally, the Company increased its adjusted earnings guidance for full-year 2016 to $6.63 - $6.73 per share.*

Worldwide Consumer sales of $3.4 billion for the second quarter 2016 represented a decrease of 1.8% versus the prior year, consisting of an operational increase of 1.5% and a negative impact from currency of 3.3%. Domestic sales increased 2.1%; international sales decreased 4.4%, which reflected an operational increase of 1.0% and a negative currency impact of 5.4%.  Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 3.9%, domestic sales increased 6.8% and international sales increased 2.0%*.  Operations in Venezuela negatively impacted worldwide Consumer operational sales growth by 120 basis points, and international sales growth by 200 basis points.

Primary contributors to Consumer operational sales results were  NEUTROGENA® and AVEENO® skin care products; over-the-counter products, including TYLENOL® and MOTRIN® analgesics, digestive health products and international anti-smoking aids; and LISTERINE® oral care products.

During the quarter, the acquisitions of NeoStrata Company, Inc., a global leader in dermocosmetics, and the HIPOGLÓS® diaper rash cream brand in Brazil were completed. In addition, subsequent to the quarter, the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal care products, was completed for $3.3 billion in cash.

Worldwide Pharmaceutical sales of $8.7 billion for the second quarter 2016 represented an increase of 8.9% versus the prior year with an operational increase of 9.7% and a negative impact from currency of 0.8%. Domestic sales increased 13.2%; international sales increased 3.1%, which reflected an operational increase of 4.9% and a negative currency impact of 1.8%.  Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 12.8%, domestic sales increased 13.9% and international sales increased 11.2%.* 

Worldwide operational sales growth was driven by new products and the strength of core products. Strong growth in new products include IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; XARELTO® (rivaroxaban), an oral anticoagulant; DARZALEX® (daratumumab), for the treatment of patients with multiple myeloma; INVOKANA®/INVOKAMET® (canagliflozin), for the treatment of adults with type 2 diabetes; and ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. New product sales growth was negatively impacted by lower sales of OLYSIO®/SOVRIAD® (simeprevir) due to competitive entrants. 

Additional contributors to operational sales growth include STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; SIMPONI®/SIMPONI ARIA® (golimumab) and REMICADE® (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; and INVEGA® SUSTENNA®/XEPLION®/TRINZA® (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

During the quarter, the U.S. Food and Drug Administration (FDA) approved an additional indication for INVOKAMET® (canagliflozin/metformin HCl) for first-line treatment of adults with type 2 diabetes and an expanded label for IMBRUVICA® (ibrutinib) to include overall survival and combination data in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The European Commission (EC) granted conditional approval to DARZALEX® (daratumumab) for monotherapy of adult patients with relapsed and refractory multiple myeloma  and also approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, TREVICTA® (paliperidone palmitate a 3 monthly injection) for the maintenance treatment of schizophrenia in adult patients, and SIMPONI® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis.

In addition, the divestiture of the company's controlled substance raw material and active pharmaceutical ingredient business to SK Capital Partners, a private equity company, was completed.

Worldwide Medical Devices sales of $6.4 billion for the second quarter 2016 represented an increase of 0.8% versus the prior year consisting of an operational increase of 1.8% and a negative currency impact of 1.0%. Domestic sales increased 1.0%; international sales increased 0.6%, which reflected an operational increase of 2.6% and a negative currency impact of 2.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 3.9%, domestic sales increased 1.9% and international sales increased 5.8%.*   Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 50 basis points.  

Primary contributors to operational sales growth were endocutters, energy and biosurgical products in the Advanced Surgery business; electrophysiology products in the Cardiovascular business; joint reconstruction  and U.S. trauma products in the Orthopaedics business; and ACUVUE® contact lenses in the Vision Care business. 

During the quarter, the acquisition of privately-held BioMedical Enterprises, Inc., a leading manufacturer of Nitinol orthopaedic implants for small bone fixation, was completed.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.  Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at www.investor.jnj.com.  Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort.  These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises.  Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the company's website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; market conditions and the possibility that the on-going share repurchase program may be suspended or discontinued; the impact of business combinations and divestitures; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release.  Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2016


2015


Total


Operations

Currency


2016


2015


Total


Operations

Currency

Sales to customers by




















segment of business








































Consumer




















    U.S.

$   1,384


1,355


2.1

%

2.1


-


$   2,742


2,714


1.0

%

1.0


-

    International

2,035


2,128


(4.4)


1.0


(5.4)


3,872


4,159


(6.9)


0.4


(7.3)


3,419


3,483


(1.8)


1.5


(3.3)


6,614


6,873


(3.8)


0.6


(4.4)





















Pharmaceutical




















    U.S.

5,144


4,543


13.2


13.2


-


10,081


8,914


13.1


13.1


-

    International

3,510


3,403


3.1


4.9


(1.8)


6,751


6,758


(0.1)


3.8


(3.9)


8,654


7,946


8.9


9.7


(0.8)


16,832


15,672


7.4


9.1


(1.7)





















Medical Devices




















    U.S.

3,044


3,013


1.0


1.0


-


6,070


5,975


1.6


1.6


-

    International

3,365


3,345


0.6


2.6


(2.0)


6,448


6,641


(2.9)


0.8


(3.7)


6,409


6,358


0.8


1.8


(1.0)


12,518


12,616


(0.8)


1.2


(2.0)





















U.S.

9,572


8,911


7.4


7.4


-


18,893


17,603


7.3


7.3


-

International

8,910


8,876


0.4


3.1


(2.7)


17,071


17,558


(2.8)


1.8


(4.6)

Worldwide

$ 18,482


17,787


3.9

%

5.3


(1.4)


$ 35,964


35,161


2.3

%

4.6


(2.3)





















 

 

 

Johnson & Johnson and Subsidiaries



















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2016


2015


Total


Operations

Currency


2016


2015


Total


Operations

Currency

Sales to customers by




















geographic area








































U.S.

$   9,572


8,911


7.4

%

7.4


-


$ 18,893


17,603


7.3

%

7.3


-





















Europe

4,090


4,151


(1.5)


(0.6)


(0.9)


7,937


8,191


(3.1)


(0.6)


(2.5)

Western Hemisphere excluding U.S.

1,542


1,501


2.7


15.4


(12.7)


2,873


3,140


(8.5)


7.1


(15.6)

Asia-Pacific, Africa

3,278


3,224


1.7


2.1


(0.4)


6,261


6,227


0.5


2.5


(2.0)

International

8,910


8,876


0.4


3.1


(2.7)


17,071


17,558


(2.8)


1.8


(4.6)





















Worldwide

$ 18,482


17,787


3.9

%

5.3


(1.4)


$ 35,964


35,161


2.3

%

4.6


(2.3)





















 

 

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER












2016


2015


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 18,482


100.0


$ 17,787


100.0


3.9

Cost of products sold

5,336


28.9


5,357


30.1


(0.4)

Selling, marketing and administrative expenses

5,176


28.0


5,384


30.3


(3.9)

Research and development expense

2,264


12.2


2,129


12.0


6.3

In-process research and development

29


0.2


-


-



Interest (income) expense, net

102


0.6


107


0.6



Other (income) expense, net

557


3.0


(931)


(5.3)



Restructuring

114


0.6


-


-



Earnings before provision for taxes on income

4,904


26.5


5,741


32.3


(14.6)

Provision for taxes on income

907


4.9


1,225


6.9


(26.0)

Net earnings

$   3,997


21.6


$   4,516


25.4


(11.5)











Net earnings per share (Diluted)

$     1.43




$     1.61




(11.2)











Average shares outstanding (Diluted)

2,794.2




2,812.0















Effective tax rate

18.5

%



21.3

%














Adjusted earnings before provision for taxes and net earnings (1)










 Earnings before provision for taxes on income

$   6,024


32.6


$   6,248


35.1


(3.6)

 Net earnings

$   4,866


26.3


$   4,812


27.1


1.1

 Net earnings per share (Diluted)

$     1.74




$     1.71




1.8

 Effective tax rate

19.2

%



23.0

%














(1) See Reconciliation of Non-GAAP Financial Measures.










 

 

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS












2016


2015


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 35,964


100.0


$ 35,161


100.0


2.3

Cost of products sold

10,665


29.6


10,639


30.2


0.2

Selling, marketing and administrative expenses

9,864


27.4


10,231


29.1


(3.6)

Research and development expense

4,277


11.9


4,028


11.5


6.2

In-process research and development

29


0.1


-


-



Interest (income) expense, net

179


0.5


226


0.6



Other (income) expense, net

518


1.4


(1,279)


(3.6)



Restructuring

234


0.7


-


-



Earnings before provision for taxes on income

10,198


28.4


11,316


32.2


(9.9)

Provision for taxes on income

1,744


4.9


2,480


7.1


(29.7)

Net earnings

$   8,454


23.5


$   8,836


25.1


(4.3)











Net earnings per share (Diluted)

$     3.02




$     3.13




(3.5)











Average shares outstanding (Diluted)

2,800.9




2,821.0















Effective tax rate

17.1

%



21.9

%














Adjusted earnings before provision for taxes and net earnings (1)










 Earnings before provision for taxes on income

$ 11,825


32.9


$ 11,878


33.8


(0.4)

 Net earnings

$   9,720


27.0


$   9,230


26.3


5.3

 Net earnings per share (Diluted)

$     3.47




$     3.27




6.1

 Effective tax rate

17.8

%



22.3

%














(1) See Reconciliation of Non-GAAP Financial Measures.










 

 

 

Johnson & Johnson and Subsidiaries















Reconciliation of Non-GAAP Financial Measures
































Second Quarter


% Incr. /



Six Months YTD


% Incr. /


(Dollars in Millions Except Per Share Data)


2016


2015


(Decr.)



2016


2015


(Decr.)

















Earnings before provision for taxes on income - as reported


$ 4,904


5,741


(14.6)

%


$ 10,198


11,316


(9.9)

%
















Intangible asset amortization expense


326


318





608


630



















Restructuring/Other (1)


141


-





278


-



















Litigation expense/(gain), net


600


134





666


(268)



















DePuy ASRHip program


-


9





-


148



















In-process research and development


29


-





29


-



















Other


24


46





46


52



















Earnings before provision for taxes on income - as adjusted


$ 6,024


6,248


(3.6)

%


$ 11,825


11,878


(0.4)

%
















Net Earnings - as reported


$ 3,997


4,516


(11.5)

%


$   8,454


8,836


(4.3)

%
















Intangible asset amortization expense


238


230





443


456



















Restructuring/Other


97


-





217


-



















Litigation expense/(gain), net


493


23





549


(230)



















DePuy ASRHip program


-


8





-


130



















In-process research and development


23


-





23


-



















Other


18


35





34


38



















Net Earnings - as adjusted 


$ 4,866


4,812


1.1

%


$   9,720


9,230


5.3

%
















Diluted Net Earnings per share - as reported


$   1.43


1.61


(11.2)

%


$     3.02


3.13


(3.5)

%
















Intangible asset amortization expense


0.08


0.08





0.16


0.16



















Restructuring/Other


0.03


-





0.08


-



















Litigation expense/(gain), net


0.18


0.01





0.19


(0.08)



















DePuy ASRHip program


-


-





-


0.05



















In-process research and development


0.01


-





0.01


-



















Other


0.01


0.01





0.01


0.01



















Diluted Net Earnings per share - as adjusted 


$   1.74


1.71


1.8

%


$     3.47


3.27


6.1

%
















Operational Diluted Net Earnings per share - as adjusted at 2014 foreign currency exchange rates




1.90







3.59



















Impact of currency at 2015 foreign currency exchange rates


$       -


(0.19)





$     0.04


(0.32)



















Operational Diluted Net Earnings per share - as adjusted at 2015 foreign currency exchange rates


$   1.74


1.71


1.8

%


$     3.51


3.27


7.3

%































(1) Includes $7M recorded in cost of products sold and $20M recorded in other (income) expense for the second quarter. 









     Includes $24M recorded in cost of products sold and $20M recorded in other (income) expense for six months YTD.







 

 

 

Johnson & Johnson and Subsidiaries









Reconciliation of Non-GAAP Financial Measure


















Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales (1)

 SECOND QUARTER 2016 ACTUAL vs. 2015 ACTUAL 











 Segments 












 Consumer 


 Pharmaceutical 


 Medical Devices 


 Total 



Operational % (2)

 WW As Reported: 


1.5%


9.7%


1.8%


5.3%

 U.S. 


2.1%


13.2%


1.0%


7.4%

 International 


1.0%


4.9%


2.6%


3.1%










Wound Care/Other









 SPLENDA®


2.5






0.5

  U.S. 


4.9






0.7

  International 


1.0






0.2










Cardiovascular









 Cordis






2.3


0.8

  U.S. 






1.1


0.4

  International 






3.5


1.3










All Other Acquisitions and Divestitures


(0.1)


(0.1)


(0.2)


(0.1)

  U.S. 


(0.2)


(0.1)


(0.2)


(0.1)

  International 


0.0


0.0


(0.3)


(0.1)










WW Ops excluding Acquisitions and Divestitures


3.9%


9.6%


3.9%


6.5%

  U.S. 


6.8%


13.1%


1.9%


8.4%

  International 


2.0%


4.9%


5.8%


4.5%










Hepatitis C




3.2




1.4

  U.S. 




0.8




0.4

  International 




6.3




2.4










WW Ops excluding Hepatitis C only




12.9%




6.7%

  U.S. 




14.0%




7.8%

  International 




11.2%




5.5%










WW Ops excluding Acquisitions, Divestitures and Hepatitis C


3.9%


12.8%


3.9%


7.9%

  U.S. 


6.8%


13.9%


1.9%


8.8%

  International 


2.0%


11.2%


5.8%


6.9%



















(1) Hepatitis C products include OLYSIO ®/SOVRIAD ®and INCIVO ®









(2) Operational growth excludes the effect of translational currency









 

 

 

Johnson & Johnson and Subsidiaries









Reconciliation of Non-GAAP Financial Measure


















Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales (1)

 SIX MONTHS 2016 ACTUAL vs. 2015 ACTUAL 











 Segments 












 Consumer 


 Pharmaceutical 


 Medical Devices 


 Total 



Operational % (2)

 WW As Reported: 


0.6%


9.1%


1.2%


4.6%

 U.S. 


1.0%


13.1%


1.6%


7.3%

 International 


0.4%


3.8%


0.8%


1.8%










Wound Care/Other









 SPLENDA®


2.3






0.4

  U.S. 


4.5






0.7

  International 


0.8






0.2










Cardiovascular









 Cordis






2.3


0.9

  U.S. 






1.1


0.4

  International 






3.5


1.4










All Other Acquisitions and Divestitures


0.0


0.2


(0.1)


0.1

  U.S. 


(0.1)


0.4


(0.1)


0.2

  International 


0.1


0.0


0.0


0.0










WW Ops excluding Acquisitions and Divestitures


2.9%


9.3%


3.4%


6.0%

  U.S. 


5.4%


13.5%


2.6%


8.6%

  International 


1.3%


3.8%


4.3%


3.4%



















Hepatitis C




3.2




1.4

  U.S. 




1.5




0.7

  International 




5.4




2.0










WW Ops excluding Hepatitis C only




12.3%




6.0%

 U.S. 




14.6%




8.0%

 International 




9.2%




3.8%










WW Ops excluding Acquisitions, Divestitures, and Hepatitis C


2.9%


12.5%


3.4%


7.4%

  U.S. 


5.4%


15.0%


2.6%


9.3%

  International 


1.3%


9.2%


4.3%


5.4%










(1) Hepatitis C products include OLYSIO ®/SOVRIAD ®and INCIVO ®









(2) Operational growth excludes the effect of translational currency


















 

 



REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2)
















BABY CARE
















US


$          102


104

-1.9%

-1.9%

-



$          197


215

-8.4%

-8.4%

-

Intl


398


439

-9.3%

-2.2%

-7.1%



754


839

-10.1%

-1.1%

-9.0%

WW


500


543

-7.9%

-2.1%

-5.8%



951


1,054

-9.8%

-2.6%

-7.2%

ORAL CARE
















US


159


147

8.2%

8.2%

-



329


305

7.9%

7.9%

-

Intl


244


244

0.0%

5.6%

-5.6%



459


489

-6.1%

1.3%

-7.4%

WW


403


391

3.1%

6.6%

-3.5%



788


794

-0.8%

3.8%

-4.6%

OTC
















US


389


366

6.3%

6.3%

-



850


771

10.2%

10.2%

-

Intl


619


608

1.8%

6.1%

-4.3%



1,177


1,196

-1.6%

4.5%

-6.1%

WW


1,008


974

3.5%

6.2%

-2.7%



2,027


1,967

3.1%

6.8%

-3.7%

SKIN CARE
















US


555


491

13.0%

13.0%

-



1,043


983

6.1%

6.1%

-

Intl


398


403

-1.2%

3.5%

-4.7%



772


814

-5.2%

1.3%

-6.5%

WW


953


894

6.6%

8.7%

-2.1%



1,815


1,797

1.0%

3.9%

-2.9%

WOMEN'S HEALTH
















US


7


7

0.0%

0.0%

-



13


13

0.0%

0.0%

-

Intl


276


313

-11.8%

-4.8%

-7.0%



521


594

-12.3%

-3.0%

-9.3%

WW


283


320

-11.6%

-4.8%

-6.8%



534


607

-12.0%

-2.9%

-9.1%

WOUND CARE / OTHER
















US


172


240

-28.3%

-28.3%

-



310


427

-27.4%

-27.4%

-

Intl


100


121

-17.4%

-14.2%

-3.2%



189


227

-16.7%

-11.4%

-5.3%

WW


272


361

-24.7%

-23.6%

-1.1%



499


654

-23.7%

-21.9%

-1.8%

















TOTAL CONSUMER
















US


1,384


1,355

2.1%

2.1%

-



2,742


2,714

1.0%

1.0%

-

Intl


2,035


2,128

-4.4%

1.0%

-5.4%



3,872


4,159

-6.9%

0.4%

-7.3%

WW


$       3,419


3,483

-1.8%

1.5%

-3.3%



$       6,614


6,873

-3.8%

0.6%

-4.4%



































REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2)
















IMMUNOLOGY
















US


$       2,224


1,876

18.6%

18.6%

-



$       4,395


3,631

21.0%

21.0%

-

Intl


814


678

20.1%

23.0%

-2.9%



1,553


1,386

12.0%

17.7%

-5.7%

WW


3,038


2,554

19.0%

19.8%

-0.8%



5,948


5,017

18.6%

20.2%

-1.6%

 REMICADE
















 US 


1,236


1,088

13.6%

13.6%

-



2,447


2,143

14.2%

14.2%

-

 US Exports (3)


185


241

-23.2%

-23.2%

-



418


422

-0.9%

-0.9%

-

 Intl


359


339

5.9%

11.1%

-5.2%



694


703

-1.3%

6.2%

-7.5%

 WW


1,780


1,668

6.7%

7.7%

-1.0%



3,559


3,268

8.9%

10.5%

-1.6%

 SIMPONI / SIMPONI ARIA
















 US


244


172

41.9%

41.9%

-



460


327

40.7%

40.7%

-

 Intl


204


136

50.0%

49.7%

0.3%



378


281

34.5%

38.3%

-3.8%

 WW


448


308

45.5%

45.4%

0.1%



838


608

37.8%

39.5%

-1.7%

 STELARA
















 US


559


375

49.1%

49.1%

-



1,070


739

44.8%

44.8%

-

 Intl


245


195

25.6%

26.4%

-0.8%



469


380

23.4%

26.8%

-3.4%

 WW


804


570

41.1%

41.4%

-0.3%



1,539


1,119

37.5%

38.7%

-1.2%

 OTHER IMMUNOLOGY
















 US


-


-

-

-

-



-


-

-

-

-

 Intl


6


8

-25.0%

-15.2%

-9.8%



12


22

-45.5%

-36.4%

-9.1%

 WW


6


8

-25.0%

-15.2%

-9.8%



12


22

-45.5%

-36.4%

-9.1%

INFECTIOUS DISEASES
















US


362


381

-5.0%

-5.0%

-



720


793

-9.2%

-9.2%

-

Intl


467


651

-28.3%

-27.3%

-1.0%



885


1,214

-27.1%

-24.8%

-2.3%

WW


829


1,032

-19.7%

-19.1%

-0.6%



1,605


2,007

-20.0%

-18.6%

-1.4%

 EDURANT
















 US


14


9

55.6%

55.6%

-



25


18

38.9%

38.9%

-

 Intl


126


92

37.0%

35.1%

1.9%



234


174

34.5%

35.2%

-0.7%

 WW


140


101

38.6%

36.9%

1.7%



259


192

34.9%

35.6%

-0.7%

 OLYSIO / SOVRIAD
















 US


21


50

-58.0%

-58.0%

-



37


148

-75.0%

-75.0%

-

 Intl


22


214

-89.7%

-89.4%

-0.3%



38


350

-89.1%

-88.5%

-0.6%

 WW


43


264

-83.7%

-83.5%

-0.2%



75


498

-84.9%

-84.5%

-0.4%

 PREZISTA / PREZCOBIX / REZOLSTA
















 US


273


258

5.8%

5.8%

-



550


492

11.8%

11.8%

-

 Intl


186


190

-2.1%

-0.6%

-1.5%



361


383

-5.7%

-2.6%

-3.1%

 WW


459


448

2.5%

3.1%

-0.6%



911


875

4.1%

5.5%

-1.4%

 OTHER INFECTIOUS DISEASES
















 US


54


64

-15.6%

-15.6%

-



108


135

-20.0%

-20.0%

-

 Intl


133


155

-14.2%

-11.2%

-3.0%



252


307

-17.9%

-13.9%

-4.0%

 WW


187


219

-14.6%

-12.5%

-2.1%



360


442

-18.6%

-15.8%

-2.8%

See footnotes at end of schedule


















REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

NEUROSCIENCE
















US


695


693

0.3%

0.3%

-



1,375


1,443

-4.7%

-4.7%

-

Intl


907


871

4.1%

4.7%

-0.6%



1,776


1,739

2.1%

5.1%

-3.0%

WW


1,602


1,564

2.4%

2.8%

-0.4%



3,151


3,182

-1.0%

0.6%

-1.6%

 CONCERTA / METHYLPHENIDATE
















 US


129


102

26.5%

26.5%

-



263


228

15.4%

15.4%

-

 Intl


109


104

4.8%

8.4%

-3.6%



206


202

2.0%

7.4%

-5.4%

 WW


238


206

15.5%

17.3%

-1.8%



469


430

9.1%

11.7%

-2.6%

 INVEGA / PALIPERIDONE
















 US


18


105

-82.9%

-82.9%

-



42


199

-78.9%

-78.9%

-

 Intl


64


61

4.9%

3.4%

1.5%



126


122

3.3%

4.4%

-1.1%

 WW


82


166

-50.6%

-51.2%

0.6%



168


321

-47.7%

-47.3%

-0.4%

 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
















 US


339


253

34.0%

34.0%

-



644


481

33.9%

33.9%

-

 Intl


221


183

20.8%

21.2%

-0.4%



429


366

17.2%

20.2%

-3.0%

 WW


560


436

28.4%

28.6%

-0.2%



1,073


847

26.7%

28.0%

-1.3%

 RISPERDAL CONSTA
















 US


100


99

1.0%

1.0%

-



195


203

-3.9%

-3.9%

-

 Intl


130


148

-12.2%

-11.9%

-0.3%



266


298

-10.7%

-8.4%

-2.3%

 WW


230


247

-6.9%

-6.7%

-0.2%



461


501

-8.0%

-6.6%

-1.4%

 OTHER NEUROSCIENCE
















 US


109


134

-18.7%

-18.7%

-



231


332

-30.4%

-30.4%

-

 Intl


383


375

2.1%

2.6%

-0.5%



749


751

-0.3%

2.6%

-2.9%

 WW


492


509

-3.3%

-3.0%

-0.3%



980


1,083

-9.5%

-7.5%

-2.0%

ONCOLOGY
















US


569


362

57.2%

57.2%

-



1,118


696

60.6%

60.6%

-

Intl


905


782

15.7%

17.1%

-1.4%



1,710


1,556

9.9%

13.5%

-3.6%

WW


1,474


1,144

28.8%

29.8%

-1.0%



2,828


2,252

25.6%

28.1%

-2.5%

 IMBRUVICA
















 US


144


89

61.8%

61.8%

-



276


155

78.1%

78.1%

-

 Intl


151


65

*

*

**



280


115

*

*

**

 WW


295


154

91.6%

93.1%

-1.5%



556


270

*

*

**

 VELCADE
















 US


-


-

-

-

-



-


-

-

-

-

 Intl


342


344

-0.6%

1.4%

-2.0%



646


683

-5.4%

-2.0%

-3.4%

 WW


342


344

-0.6%

1.4%

-2.0%



646


683

-5.4%

-2.0%

-3.4%

 ZYTIGA
















 US


286


255

12.2%

12.2%

-



558


508

9.8%

9.8%

-

 Intl


315


291

8.2%

8.4%

-0.2%



601


594

1.2%

4.1%

-2.9%

 WW


601


546

10.1%

10.2%

-0.1%



1,159


1,102

5.2%

6.8%

-1.6%

 OTHER ONCOLOGY
















 US


139


18

*

*

-



284


33

*

*

-

 Intl


97


82

18.3%

20.1%

-1.8%



183


164

11.6%

15.6%

-4.0%

 WW


236


100

*

*

**



467


197

*

*

**

CARDIOVASCULAR / METABOLISM / OTHER
















US


1,294


1,231

5.1%

5.1%

-



2,473


2,351

5.2%

5.2%

-

Intl


417


421

-1.0%

3.2%

-4.2%



827


863

-4.2%

1.4%

-5.6%

WW


1,711


1,652

3.6%

4.7%

-1.1%



3,300


3,214

2.7%

4.2%

-1.5%

 XARELTO
















 US


594


472

25.8%

25.8%

-



1,161


913

27.2%

27.2%

-

 Intl


-


-

-

-

-



-


-

-

-

-

 WW


594


472

25.8%

25.8%

-



1,161


913

27.2%

27.2%

-

 INVOKANA / INVOKAMET
















 US


348


302

15.2%

15.2%

-



645


568

13.6%

13.6%

-

 Intl


35


16

*

*

**



63


28

*

*

**

 WW


383


318

20.4%

21.0%

-0.6%



708


596

18.8%

19.5%

-0.7%

 PROCRIT / EPREX
















 US


230


179

28.5%

28.5%

-



413


342

20.8%

20.8%

-

 Intl


92


97

-5.2%

-2.9%

-2.3%



183


203

-9.9%

-5.9%

-4.0%

 WW


322


276

16.7%

17.5%

-0.8%



596


545

9.4%

10.9%

-1.5%

 OTHER
















 US


122


278

-56.1%

-56.1%

-



254


528

-51.9%

-51.9%

-

 Intl


290


308

-5.8%

-1.4%

-4.4%



581


632

-8.1%

-2.5%

-5.6%

 WW


412


586

-29.7%

-27.4%

-2.3%



835


1,160

-28.0%

-25.0%

-3.0%

















TOTAL PHARMACEUTICAL
















US


5,144


4,543

13.2%

13.2%

-



10,081


8,914

13.1%

13.1%

-

Intl


3,510


3,403

3.1%

4.9%

-1.8%



6,751


6,758

-0.1%

3.8%

-3.9%

WW


$       8,654


7,946

8.9%

9.7%

-0.8%



$     16,832


15,672

7.4%

9.1%

-1.7%

















See footnotes at end of schedule


















REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

MEDICAL DEVICES SEGMENT (2) (4)
















CARDIOVASCULAR
















US


$          235


235

0.0%

0.0%

-



$          466


463

0.6%

0.6%

-

Intl


235


309

-23.9%

-23.8%

-0.1%



447


610

-26.7%

-25.0%

-1.7%

WW


470


544

-13.6%

-13.6%

0.0%



913


1,073

-14.9%

-14.0%

-0.9%

DIABETES CARE
















US


177


214

-17.3%

-17.3%

-



357


426

-16.2%

-16.2%

-

Intl


294


280

5.0%

7.0%

-2.0%



543


552

-1.6%

2.2%

-3.8%

WW


471


494

-4.7%

-3.5%

-1.2%



900


978

-8.0%

-5.8%

-2.2%

DIAGNOSTICS
















US


-


-

-

-

-



-


-

-

-

-

Intl


31


16

93.8%

*

**



59


46

28.3%

47.8%

-19.5%

WW


31


16

93.8%

*

**



59


46

28.3%

47.8%

-19.5%

ORTHOPAEDICS
















US 


1,364


1,321

3.3%

3.3%

-



2,756


2,630

4.8%

4.8%

-

Intl


991


1,009

-1.8%

0.2%

-2.0%



1,940


2,028

-4.3%

-0.5%

-3.8%

WW


2,355


2,330

1.1%

2.0%

-0.9%



4,696


4,658

0.8%

2.4%

-1.6%

 HIPS
















 US


197


193

2.1%

2.1%

-



400


383

4.4%

4.4%

-

 Intl


152


143

6.3%

9.6%

-3.3%



291


286

1.7%

6.5%

-4.8%

 WW


349


336

3.9%

5.3%

-1.4%



691


669

3.3%

5.3%

-2.0%

 KNEES
















 US


229


222

3.2%

3.2%

-



473


448

5.6%

5.6%

-

 Intl


156


150

4.0%

6.7%

-2.7%



301


300

0.3%

4.4%

-4.1%

 WW


385


372

3.5%

4.6%

-1.1%



774


748

3.5%

5.1%

-1.6%

 TRAUMA
















 US


381


351

8.5%

8.5%

-



762


715

6.6%

6.6%

-

 Intl


255


270

-5.6%

-3.8%

-1.8%



516


562

-8.2%

-4.4%

-3.8%

 WW


636


621

2.4%

3.2%

-0.8%



1,278


1,277

0.1%

1.8%

-1.7%

 SPINE & OTHER
















 US


557


555

0.4%

0.4%

-



1,121


1,084

3.4%

3.4%

-

 Intl


428


446

-4.0%

-2.5%

-1.5%



832


880

-5.5%

-2.2%

-3.3%

 WW


985


1,001

-1.6%

-0.9%

-0.7%



1,953


1,964

-0.6%

0.9%

-1.5%

SURGERY
















US


1,020


1,000

2.0%

2.0%

-



2,001


1,960

2.1%

2.1%

-

Intl


1,377


1,328

3.7%

6.4%

-2.7%



2,624


2,624

0.0%

4.4%

-4.4%

WW


2,397


2,328

3.0%

4.6%

-1.6%



4,625


4,584

0.9%

3.4%

-2.5%

 ADVANCED
















 US


389


360

8.1%

8.1%

-



741


689

7.5%

7.5%

-

 Intl


520


480

8.3%

11.0%

-2.7%



984


921

6.8%

11.3%

-4.5%

 WW


909


840

8.2%

9.7%

-1.5%



1,725


1,610

7.1%

9.7%

-2.6%

 GENERAL
















 US


421


423

-0.5%

-0.5%

-



840


845

-0.6%

-0.6%

-

 Intl


706


696

1.4%

3.9%

-2.5%



1,357


1,407

-3.6%

0.5%

-4.1%

 WW


1,127


1,119

0.7%

2.3%

-1.6%



2,197


2,252

-2.4%

0.2%

-2.6%

 SPECIALTY
















 US


210


217

-3.2%

-3.2%

-



420


426

-1.4%

-1.4%

-

 Intl


151


152

-0.7%

2.8%

-3.5%



283


296

-4.4%

1.0%

-5.4%

 WW


361


369

-2.2%

-0.7%

-1.5%



703


722

-2.6%

-0.4%

-2.2%

VISION CARE
















US


248


243

2.1%

2.1%

-



490


496

-1.2%

-1.2%

-

Intl


437


403

8.4%

8.1%

0.3%



835


781

6.9%

8.9%

-2.0%

WW


685


646

6.0%

5.8%

0.2%



1,325


1,277

3.8%

5.0%

-1.2%

















TOTAL MEDICAL DEVICES
















US


3,044


3,013

1.0%

1.0%

-



6,070


5,975

1.6%

1.6%

-

Intl


3,365


3,345

0.6%

2.6%

-2.0%



6,448


6,641

-2.9%

0.8%

-3.7%

WW


$       6,409


6,358

0.8%

1.8%

-1.0%



$     12,518


12,616

-0.8%

1.2%

-2.0%

















* Percentage greater than 100%
















** Not meaningful
















(1) Operational growth excludes the effect of translational currency














(2) Unaudited
















(3) Reported as U.S. sales
















(4) Prior year amounts have been reclassified to conform to current year product disclosure



























 

SOURCE Johnson & Johnson

This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.